Season 3 - Ep.20: ICD indications in primary prevention - Drug treatment of cardiac amyloidosis

Jul 17, 2025

This discussion features Marianna Fontana, a Professor of Cardiology and Consultant at the National Amyloidosis Center, who shares insights on cutting-edge drug treatments for cardiac amyloidosis. Carlos Aguiar reviews recent studies, notably the evolving criteria for ICD use in primary prevention, advocating for personalized approaches in cardiac care. The conversation dives into new therapies, including stabilizers and gene silencers, as well as surprising myths about neckties in healthcare. Tune in for a blend of serious research and lighthearted myth-busting!

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Personalize ICD Indications

Primary prevention ICD indications need personalization beyond left ventricular ejection fraction and heart failure class.
MRI fibrosis extent and genetic risk factors improve risk stratification for sudden cardiac death.

ADVICE

Individualize ICD Replacement Decisions

Evaluate the patient's current risk and heart function before routinely replacing ICD batteries.
Discuss thoroughly with patients to decide if device replacement or explantation is appropriate.

ADVICE

Amyloidosis Drug Treatment Strategies

Stabilizers and gene silencers delay transthyretin cardiac amyloidosis progression effectively.
Combination therapy might be superior, pending further trial data confirmations.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
ICD Indications in primary prevention
Drug treatment of cardiac amyloidosis
Mythbusters

Host: Rick Grobbee

Guests: Carlos Aguiar, Gerhard Hindricks, Marianna Fontana

Want to watch that episode? Go to: https://esc365.escardio.org/event/1810

Disclaimer:

ESC TV Today is supported by Bristol Myers Squibb and Novartis.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

The ESC is not liable for any translated content of this video. The English-language always prevails.

Declarations of interests:

Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.